Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

May 6, 2023

https://www.globenewswire.com/news-release/2023/05/06/2662917/0/en/Deucrictibant-Data-Highlighted-in-Multiple-Presentations-at-the-C1-Inhibitor-Deficiency-and-Angioedema-Workshop.html

ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations highlighting data from non-clinical and clinical studies of deucrictibant at the 13th C1-inhibitor Deficiency and Angioedema Workshop, being held from May 4-7, 2023, in Budapest, Hungary.

Read more at globenewswire.com

Related news for (PHVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.